Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL732996 | 0.95 | TSHR (0.50) | LMNACREBBPNCOA1NCOA3TSHR | |
| SCHEMBL9276266 | 0.90 | LMNA (0.51) | LMNACREBBPNCOA1NCOA3TSHR | |
| SCHEMBL25902203 | 0.89 | LMNA (0.49) | LMNACREBBPNCOA1NCOA3TSHR | |
| SCHEMBL289285 | 0.86 | CA12 (0.55) | LMNANCOA1NCOA3TSHRKMT2A | |
| SCHEMBL644548 | 0.84 | EGFR (0.47) | LMNATSHRKDM4EL3MBTL1NOTUM | |
| SCHEMBL28030473 | 0.84 | TSHR (0.66) | LMNATSHRKMT2AMEN1GAA | |
| SCHEMBL29633582 | 0.84 | KDM4E (0.51) | LMNACREBBPTSHRKMT2AKDM4E | |
| SCHEMBL25980852 | 0.83 | LMNA (0.52) | LMNACREBBPNCOA1NCOA3TSHR | |
| SCHEMBL16049802 | 0.82 | LMNA (0.51) | LMNACREBBPNCOA1NCOA3TSHR | |
| SCHEMBL3576601 | 0.82 | LMNA (0.57) | LMNACREBBPNCOA1NCOA3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710668-B | Condensed azines for EP300 or CBP modulation and indications thereof | OPNA生物公司 | 2025-01-07 | — | — | CN | disclosed |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | OPNA IMMUNO-ONCOLOGY SA (CH) | 2022-09-20 | — | — | US | disclosed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| CN-113710668-A | Condensed azines for EP300 or CBP modulation and indications therefor | 普莱希科公司 | 2021-11-26 | — | — | CN | disclosed |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | Opna Bio SA (CH) | 2021-10-14 | — | — | US | disclosed |
| WO-2020210366-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-2307422-B1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD KK (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8524730-B2 | Spirochromanone carboxylic acids | MSD K.K. (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-2120569-B1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME (US) | 2013-08-14 | — | — | EP | disclosed |
| US-8138197-B2 | Spirochromanon derivatives | MSD K.K. (JP) | 2012-03-20 | — | — | US | disclosed |
| EP-2307422-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | Banyu Pharmaceutical Co., Ltd. (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | MSD K.K. (JP) | 2011-03-31 | — | — | US | disclosed |
| WO-2010002010-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-01-07 | — | — | WO | disclosed |
| EP-2120569-A2 | SPIROCHROMANON DERIVATIVES | Merck & Co., Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | MERCK SHARP & DOHME LLC | 2009-10-29 | — | — | US | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008088692-A2 | SPIROCHROMANON DERIVATIVES | MERCK & CO., INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270436-A1 | SPIROCHROMANON DERIVATIVES | AKR1C3, CBR3, AKR1C4 | LMNA 2503/4885CREBBP 3128/4885NCOA1 351/4885 |
| US-20110077262-A1 | NOVEL SPIROCHROMANONE CARBOXYLIC ACIDS | CNKSR1, CBR1, CBR3 | LMNA 1932/4885CREBBP 2380/4885NCOA1 334/4885 |
| US-11446287-B2 | Compounds and methods for EP300 or CBP modulation and indications therefor | EP300, CREBBP, HDAC11 | LMNA 637/4885CREBBP 2/4885NCOA1 10/4885 |
| US-20210315872-A1 | COMPOUNDS AND METHODS FOR EP300 or CBP MODULATION AND INDICATIONS THEREFOR | EP300, CREBBP, HDAC11 | LMNA 641/4885CREBBP 2/4885NCOA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.